soul trial oral semaglutide Breaking* Top-line results positive of the highly anticipated #SOUL trial, the first powered CVOT of an #GLP1RA 14% reduction in MACE with oral among 9,650 people with T2D and established Projected impact of oral semaglutide
Description
The search for an ideal drug or Holy Grail within this landscape of possible agents continues, as weight reduction is achieved only in less than 10% of patients
However, it also turns out that interaction of GLP-1 agonists with receptors found on brain cells leads to feelings of satiety and reduced hunger
Make sure your Digital Nourish is in your cart with your GLP-1 program to get it free
30 tablets
Jill Carnahan for a powerful, research-informed, and deeply compassionate conversation
Heres what you need to know about the diabetes drug and other new medicines used for weight loss.
